ASCO Education

Cancer Topics - Recent Approvals: Erdafitinib and Enfortumab for Second-Line Treatment of Metastatic Bladder Cancer

02.12.2020 - By American Society of Clinical Oncology (ASCO)Play

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Dr. Winston Tan, Medical Oncologist at Mayo Clinic, discusses the recent FDA approval of erdafitinib and enfortumab for second-line treatment of metastatic bladder cancer.

More episodes from ASCO Education